SST and autosomal dominant polycystic kidney disease: Since tolvaptan can effectively slow the rate of disease progression in ADPKD by inhibiting renal cAMP production [10, 11] and stimulate diuresis by blocking vasopressin at the collecting duct, SST levels could theoretically be influenced during treatment with tolvaptan.